Dyadic International, Inc. (NASDAQ:DYAI – Get Free Report)’s stock price passed below its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $1.36 and traded as low as $1.22. Dyadic International shares last traded at $1.23, with a volume of 7,944 shares changing hands.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reissued a “buy” rating and set a $6.00 price target on shares of Dyadic International in a research report on Monday, July 8th.
Get Our Latest Stock Analysis on DYAI
Dyadic International Stock Down 0.8 %
Dyadic International (NASDAQ:DYAI – Get Free Report) last posted its earnings results on Tuesday, August 13th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.01). Dyadic International had a negative net margin of 428.86% and a negative return on equity of 145.95%. The company had revenue of $0.39 million for the quarter, compared to the consensus estimate of $1.00 million. During the same quarter in the prior year, the company posted ($0.07) EPS. Analysts expect that Dyadic International, Inc. will post -0.26 EPS for the current year.
Institutional Investors Weigh In On Dyadic International
A hedge fund recently raised its stake in Dyadic International stock. Chapin Davis Inc. grew its holdings in shares of Dyadic International, Inc. (NASDAQ:DYAI – Free Report) by 2.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 847,301 shares of the biotechnology company’s stock after acquiring an additional 21,000 shares during the period. Chapin Davis Inc. owned about 2.90% of Dyadic International worth $1,254,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 27.95% of the stock is owned by hedge funds and other institutional investors.
About Dyadic International
Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.
Read More
- Five stocks we like better than Dyadic International
- 3 Healthcare Dividend Stocks to Buy
- Palo Alto Analysts Drive it to New Highs: 50% Upside Is Possible
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Roblox’s Growth Beyond Kids: Stock Set for Major Moves
- Conference Calls and Individual Investors
- 5 Oversold Stocks to Buy Right Now
Receive News & Ratings for Dyadic International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyadic International and related companies with MarketBeat.com's FREE daily email newsletter.